Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024;247(1):19-29.
doi: 10.1159/000533443. Epub 2023 Aug 14.

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis

Andrew Mihalache  1 , Amin Hatamnejad  2 , Nikhil S Patil  2 , Marko M Popovic  3 , Peter J Kertes  3   4 , Miguel Cruz-Pimentel  3 , Rajeev H Muni  3   5
Affiliations
Meta-Analysis

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis

Andrew Mihalache et al. Ophthalmologica. 2024.

Abstract

Background: The comparative safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular edema (DME) and macular edema (ME) secondary to retinal vein occlusion (RVO) is unclear.

Objectives: This meta-analysis aimed to compare the safety and efficacy of different doses of IVTA in this setting.

Methods: A systematic literature search for randomized clinical trials (RCTs) was conducted on Cochrane Library, Ovid MEDLINE, and EMBASE from January 2005 to May 2022. Studies that reported on patients with DME or ME secondary to RVO that received treatment with different doses of IVTA were included. A random-effects meta-analysis was performed. Cochrane's Risk of Bias Tool 2 was used to assess the risk of bias, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidelines were used to assess certainty of evidence.

Results: Five RCTs reporting on 1,041 eyes at baseline were included in this meta-analysis. In eyes with ME secondary to RVO, high-dose (4 mg) IVTA achieved a significantly better change in best-corrected visual acuity (WMD = -4.75 ETDRS letters, 95% CI = [-7.73, -1.78], p = 0.002) and reduction in retinal thickness (WMD = -93.02 μm, 95% CI = [-153.23, -32.82], p = 0.002) at months 4-6 compared to low-dose (1-2 mg) IVTA. However, high-dose IVTA had a higher risk of intraocular pressure-related adverse events (RR = 2.99, 95% CI = [1.05, 8.50], p = 0.04) and cataract surgery (RR = 5.67, 95% CI = [3.09, 10.41], p < 0.00001) than low-dose IVTA in eyes with ME secondary to RVO. These efficacy and safety differences in high-dose and low-dose IVTA were not observed in DME eyes.

Conclusions: The RCT evidence in this setting is limited. High-dose IVTA achieved greater improvements in visual acuity and reductions in retinal thickness than low-dose IVTA at months 4-6. However, high-dose IVTA had a less favorable safety profile than low-dose IVTA. The significance of these outcomes was based on patients with ME secondary to RVO, but not DME.

Keywords: Diabetic macular edema; Retinal vein occlusion; Triamcinolone acetonide.

PubMed Disclaimer

Conflict of interest statement

A.M., A.H., N.S.P., and M.C.P. have no conflicts of interest to declare. M.M.P.: Financial support (to institution) – PSI Foundation, Fighting Blindness Canada. P.J.K.: Advisory board – Novartis, Alcon, Bayer, Roche, Allergan, Novelty Nobility; Financial support (to institution) – Bayer, Roche, Novartis; Financial support – Novartis, Bayer, Roche, Boehringer Ingelheim, Pfizer, Zeiss; Equity owner – ArcticDx. R.H.M.: Advisory board- Alcon, Bausch + Lomb, Bayer, Novartis, Allergan, Roche; Financial Support (to institution)- Bayer, Novartis, Roche.

Figures

Fig. 1.
Fig. 1.
Flowchart summarizing study screening and selection process.
Fig. 2.
Fig. 2.
Forest plots comparing low-dose and high-dose IVTA in eyes with DME, depicting change in BCVA at weeks 1–4 (a), change in BCVA at months 2–3 (b), and change in BCVA at months 4–6 (c).
Fig. 3.
Fig. 3.
Forest plot comparing low-dose and high-dose IVTA in eyes with DME, depicting change in RT at months 4–6.
Fig. 4.
Fig. 4.
Forest plot comparing low-dose and high-dose IVTA in eyes with DME, depicting IOP-related adverse events.
Fig. 5.
Fig. 5.
Forest plots comparing low-dose and high-dose IVTA in eyes with ME secondary to RVO, depicting change in BCVA at months 4–6 (a), change in BCVA at months 7–9 (b), and change in BCVA at months 10–12 (c).
Fig. 6.
Fig. 6.
Forest plots comparing low-dose and high-dose IVTA in eyes with ME secondary to RVO, depicting change in RT at months 4–6 (a) and change in RT at months 10–12 (b).
Fig. 7.
Fig. 7.
Forest plots comparing low-dose and high-dose IVTA in eyes with ME secondary to RVO, depicting IOP-related adverse events (a), cataract surgery (b), glaucoma surgery (c), subconjunctival hemorrhage (d), cataract progression (e), vitreous hemorrhage (f), and vitreous floaters (g).
See this image and copyright information in PMC

References

    1. Schwartz SG, Flynn HW, Scott IU. Intravitreal corticosteroids in the management of diabetic macular edema. Curr Ophthalmol Rep. 2013;1(3):144–9. 10.1007/s40135-013-0015-3. - DOI - PMC - PubMed
    1. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123–162. 10.1159/000502041. - DOI - PubMed
    1. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004 Nov;111(11):2044–9. 10.1016/j.ophtha.2004.05.025. - DOI - PubMed
    1. Patil NS, Hatamnejad A, Mihalache A, Popovic MM, Kertes PJ, Muni RH. Anti-vascular endothelial growth factor treatment compared with steroid treatment for retinal vein occlusion: a meta-analysis. Ophthalmologica. 2022;245(6):500–515. 10.1159/000527626. - DOI - PubMed
    1. Ghoraba HH, Leila M, Elgouhary SM, Elgemai EEM, Abdelfattah HM, Ghoraba HH, et al. Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middleincome countries. Clin Ophthalmol. 2018 Nov 26;12:2383–2391. 10.2147/opth.s185274. - DOI - PMC - PubMed

MeSH terms